Shares in Eli Lilly (NYSE:LLY) fell slightly this morning even though the pharmaceutical company beat analysts’ estimates with its fourth quarter and full-year financial results. The Indianapolis-based company swung to a net loss in the fourth quarter, posting -$1.7 billion, or $1.85 per share, on sales of $6.2 billion for the 3 months ended Dec. 31, for sales […]
Diabetes
Welcome to MassDevice's Diabetes Hub, your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Here are top diabetes features from MassDevice and its sister publications (and scroll down to read the latest diabetes device news from MassDevice):
+ These diabetes devices are set to launch in 2024
+ The top IVD and diabetes tech stories of 2023
+ How Dexcom designed a new “life-changing” sensor for even more people with diabetes
+ Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump
+ The 10 biggest diabetes tech stories from 2023
Latest Diabetes News
Dexcom takes on Abbott in head-to-head glucose monitoring trial
Updated to include a statement from Abbott. Dexcom (NSDQ:DXCM) touted data today from a head-to-head trial comparing its G5 mobile continuous glucose monitoring system with Abbott‘s (NYSE:ABT) recently-approved FreeStyle Libre Flash glucose monitoring system. The I-Hart study, which enrolled 40 people with Type I diabetes, found that Dexcom’s device reduced patients’ time spent in hypoglycemia by 43 […]
Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug
Boehringer Ingelheim has inked an outcomes-based contract with pharmacy benefit manager Prime Therapeutics for its oral Type II diabetes drug, Jardiance. The medication is designed to cut the risk of cardiovascular death in adult patients with Type II diabetes and established heart disease. Get the full story at our sister site, Drug Delivery Business News.
European committee backs Mylan’s insulin glargine biosimilar
Mylan (NSDQ:MYL) and Biocon announced today that a European Medicines Agency committee has recommended approval for its biosimilar insulin glargine, Semglee. The committee’s positive opinion brings the product one step closer to approval. The European Commission is slated to make a final decision in April. Get the full story at our sister site, Drug Delivery Business News.
Report: Advocacy groups urge Congress to fund diabetes research program
Advocacy groups have reportedly warned Congress that if lawmakers don’t find permanent funding solutions for diabetes research programs, it could jeopardize important work being done around the country to help people living with diabetes. Politicians on Capitol Hill have provided funding that will support the Special Diabetes Program and the Special Diabetes Program for Indians through […]
Senseonics prices $50m notes offering, touts Q4 and full-year prelims
Senseonics (NYSE:SENS) announced today an underwritten offering of $50 million in 5.25% convertible senior notes due 2023, alongside a 30-day option for underwriters to buy up to an additional $7.5 million in notes to cover over-allotments. The notes, which mature on Feb. 1, 2023, will be convertible into shares of Senseonics’ common stock at approximately $3.40 […]
Global sales for Abbott’s diabetes biz jumps 33% in Q4
Worldwide sales for Abbott‘s (NYSE:ABT) diabetes business jumped 33% in the fourth quarter of 2017, the company reported, driven largely by its FreeStyle Libre continuous glucose monitoring system. The device is the only CGM system on the market that is calibrated at the factory and eliminates the need for people with diabetes to perform routine fingersticks. Get the […]
Nemaura uplists shares to NASDAQ exchange
Nemaura Medical (OTC:NMRD) said today that shares of its common stock were approved to list on the NASDAQ exchange. The medtech company’s shares are slated to start trading on Jan. 25 under its existing symbol. Get the full story at our sister site, Drug Delivery Business News.
Glytec touts patient outcomes for diabetes management system
Four new studies were published in this month’s issue of the Journal of Diabetes Science and Technology touting patient outcomes linked to Glytec‘s eGlycemic diabetes management system, the company reported. In both inpatient and outpatient settings, the use of eGMS for insulin therapy management was safer and more effective than traditional standards of care. The studies reported lower […]
SFC Fluidics inks deal with JDRF to develop automated insulin delivery system
SFC Fluidics has inked a two-year deal with JDRF to develop an automated insulin delivery system that combines a continuous glucose monitor and an insulin delivery algorithm into a single disposable device. JDRF is slated to provide funding to the medical device company as part of its Artificial Pancreas Project, which aims to accelerate the development of commercially […]
DarioHealth launches iPhone-compatible glucose meter in Australia
DarioHealth (NSDQ:DRIO) said today that the Lightning-enabled version of its blood glucose monitoring system is available in Australia. The device is designed to connect with the latest Apple products, including the iPhone 7, iPhone 8 and iPhone X. The product’s launch comes just one month after it won approval from Australian authorities. Get the full story at […]